20.96
0.97 (4.85%)
| Previous Close | 19.99 |
| Volume | 742,021 |
| Price / Earnings (Forward) | 17.38 |
| Price / Sales | 1.31 |
| Price / Book | 1.11 |
| 52 Weeks Range |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Bausch + Lomb Corporation | Mixed | Bullish |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.1 |
| Timing 35% | 2.0 |
| AI Technical info | NA |
| Technical Oscillators info | 4.0 |
| Technical Moving Averages info | -1.0 |
| Smart Money 30% | -0.2 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | -0.6 |
| Environment | ×0.90 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | +5.5% |
| Pillar Agreement | ×1.16 |
| Not in score | |
| Price Volatility info | -4.6 |
| Final Score | 0.65 |
Select this tab to load the latest available analysis.
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.13% |
| % Held by Institutions | 10.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Clark Estates Inc/Ny | 30 Jun 2026 | 881,000 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALFONSO EDUARDO | 20.40 | - | 1,125 | 22,950 |
| MUNSCH FREDERICK | - | 20.40 | -112,015 | -2,285,106 |
| PAULSON JOHN | 20.40 | - | 1,125 | 22,950 |
| ROBERTSON RUSSEL C | 20.40 | - | 1,256 | 25,622 |
| Aggregate Net Quantity | -108,509 | |||
| Aggregate Net Value ($) | -2,213,584 | |||
| Aggregate Avg. Buy ($) | 20.40 | |||
| Aggregate Avg. Sell ($) | 20.40 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ALFONSO EDUARDO | Director | 29 Oct 2026 | Acquired (+) | 1,125 | 20.40 | 22,950 |
| PAULSON JOHN | Director | 29 Oct 2026 | Acquired (+) | 1,125 | 20.40 | 22,950 |
| ROBERTSON RUSSEL C | Director | 29 Oct 2026 | Acquired (+) | 1,256 | 20.40 | 25,622 |
| MUNSCH FREDERICK | Officer | 29 Oct 2026 | Sell (-) | 112,015 | 20.40 | 2,285,106 |
| MUNSCH FREDERICK | Officer | 29 Oct 2026 | Option execute | 112,015 | - | - |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |